Vivos Therapeutics (VVOS) Change in Accured Expenses (2020 - 2026)

Vivos Therapeutics (VVOS) has 7 years of Change in Accured Expenses data on file, last reported at $125000.0 in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at $125000.0, up 127.78% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.2 million (up 775.2% YoY), and the FY2025 annual result was $3.6 million, up 9376.92% from the prior year.
• Change in Accured Expenses retreated to $125000.0 in Q1 2026 per VVOS's latest filing, from $2.6 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $2.6 million in Q4 2025 and troughed at -$538000.0 in Q3 2022.
• A 5-year average of $228764.7 and a median of $33000.0 in 2023 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2024 and 2025: Change in Accured Expenses tumbled 506.06% in 2024, then soared 113000.0% in 2025.
• A 5-year view of Change in Accured Expenses shows it stood at $788000.0 in 2022, then slumped by 106.73% to -$53000.0 in 2023, then grew by 28.3% to -$38000.0 in 2024, then jumped by 6978.95% to $2.6 million in 2025, then tumbled by 95.22% to $125000.0 in 2026.
• Business Quant data shows VVOS's Change in Accured Expenses at $125000.0 in Q1 2026, $2.6 million in Q4 2025, and $1.1 million in Q3 2025.